|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.10 EUR | -0.87% |
|
-1.12% | -0.08% |
| 07/05 | Bayer says China's Center of Drug Evaluation grants Priority Review designation for Asundexian | RE |
| 07/05 | Bayer says iodine-124 evuzamitide meets phase III endpoints in cardiac amyloidosis | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 4.33TCr | |||||
| 87TCr | |||||
| 54TCr | |||||
| 36TCr | |||||
| 33TCr | |||||
| 28TCr |
- Stock Market
- Equities
- BAYN Stock
- Charts Bayer AG
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition